Sonoma PharmaceuticalsSNOA
SNOA
About: Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Employees: 171
0
Funds holding %
of 7,290 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.58% less ownership
Funds ownership: 2.08% [Q3] → 1.5% (-0.58%) [Q4]
31% less funds holding
Funds holding: 13 [Q3] → 9 (-4) [Q4]
37% less capital invested
Capital invested by funds: $85.7K [Q3] → $54.2K (-$31.4K) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for SNOA.
Financial journalist opinion
Neutral
Accesswire
2 weeks ago
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results
Revenues increased 14% for the quarter compared to prior year and 13% year-to-date Positive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024 Year-to-date net loss decline of $1.1 million BOULDER, CO / ACCESS Newswire / February 5, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its third fiscal quarter and nine months ended December 31, 2024. "We are pleased to report another strong quarter with increased revenues, positive cash flow from operations, and operating expenses remaining flat in an inflationary period," remarked Amy Trombly, CEO of Sonoma.
Neutral
Accesswire
2 months ago
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it has successfully completed transition to the new European Union (EU) Medical Device Regulation (MDR) for four of its products in Europe. Sonoma was granted classification as a Class IIb medical device for Microdacyn60® Wound Care and Microdacyn60 Hydrogel, its scar gel product Epicyn®, and Pediacyn® for atopic dermatitis.
Positive
Zacks Investment Research
2 months ago
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Neutral
Accesswire
3 months ago
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the relaunch of its prescription dermatology and eye care products lines. The prescription-strength products include: Acuicyn® Eyelid & Eyelash Hygiene, Epicyn® Facial Cleanser, Levicyn® Dermal Spray, Levicyn® Gel, Levicyn® Spray Gel and Celacyn® Scar Management Gel.
Neutral
Accesswire
3 months ago
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based hydrogel, including improved biocompatibility and extended shelf life. Per this new clearance, Sonoma's Microdacyn® Hydrogel can be used under the supervision of a healthcare professional for management of wounds associated with dermal irritation, sores, injuries and ulcers of dermal tissue, for use on first and second degree burns, and diabetic ulcers, and for the management of mechanically or surgically debrided wounds.
Neutral
Accesswire
3 months ago
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results
Revenue increased 31% for the quarter compared to same period prior year Positive cash flows from operations of $0.35 million for the quarter Net loss improved 59% for the quarter compared to same period prior year Net loss per share improved 90% for the quarter compared to same period prior year BOULDER, CO / ACCESSWIRE / November 7, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced financial results for its second fiscal quarter ended September 30, 2024. "Our results this quarter reflect the diligent efforts by Sonoma's team to grow our business and drive toward profitability," said Amy Trombly, CEO of Sonoma.
Neutral
Accesswire
3 months ago
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf
BOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at MEDICA 2024 in Düsseldorf, Germany November 11-14, 2024. MEDICA is considered the largest and most prestigious medical trade fair in the world, expected to attract over 120,000 visitors from more than 70 countries and over 5,300 exhibitors, showcasing the latest innovations in medical technology, diagnostics, and healthcare IT.
Neutral
Accesswire
4 months ago
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada
BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into an amendment to its distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in Canada. As previously announced, on August 19, 2024, Sonoma entered into a distribution agreement with a global healthcare distributor for the marketing and distribution of its wound care products in the United States, to be sold through hospital systems and other healthcare channels.
Neutral
Accesswire
4 months ago
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences
BOULDER, CO / ACCESSWIRE / October 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it will be presenting at two upcoming investor conferences. Danisavage Financial Strategies Virtual 1x1 Investor Conference Sonoma is scheduled to present on Thursday, October 24 at 2:00pm ET at the Danisavage Financial Strategies Virtual 1x1 Investor Conference.
Neutral
Accesswire
5 months ago
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
BOULDER, CO / ACCESSWIRE / September 19, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it received a formal determination letter from Nasdaq notifying Sonoma that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market and the matter is now closed. As previously reported, On September 22, 2023, Sonoma received a letter from Nasdaq indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the Nasdaq Capital Market.
Charts implemented using Lightweight Charts™